OTC$EVFM
Evofem Biosciences Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Evofem Biosciences reported financial results for Q4 2020, marked by the U.S. commercial launch of Phexxi and increase in consumer awareness.
Evofem Biosciences reported net product sales of $170,000 for the fourth quarter of 2020, their first full quarter of product sales after launching Phexxi. The company's "Get Phexxi" DTC campaign generated over 115 million views in its first two weeks, leading to increased consumer awareness.
- "Get Phexxi" generated over 115 million views across all media platforms in its first two weeks, leading to an increase in consumer awareness of Phexxi and in telehealth activity.
- More than 2,650 healthcare providers have prescribed Phexxi since launch.
- First quarter 2021 Phexxi unit shipments to wholesalers are on track to exceed full-year 2020 levels.
- Secured a $25 million strategic investment from Adjuvant Capital at a premium to market, with proceeds earmarked to fund the pivotal EVOGUARD trial and expand global market access for Phexxi.
Headline financials
Revenue & EPS history
Evofem Biosciences · Revenue · Quarterly
$168K
Revenue by segment
Evofem Biosciences · $170K total across 1 segment · Q4 2020
- Product Sales$170K—100.0%
Forward guidance
Evofem Biosciences' forward guidance was not included in this report.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2020
-4.2%
Avg return
Earnings day
-6.2%
Avg return
5 days after
-6.7%
Avg return
30 days after
29%
13 / 45 earnings
Positive
+32.4%
Q4 2023
Best reaction
-36.7%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | -4.5% | +19.7% | |
| Q3 2025 | +11.1% | +11.1% | +33.3% | |
| Q2 2025 | +11.1% | +11.1% | +77.8% | |
| Q1 2025 | +12.5% | +12.5% | +25.0% | |
| Q3 2024 | -16.5% | -16.7% | -16.7% | |
| Q2 2024 | +6.4% | +11.1% | +0.0% | |
| Q1 2024 | -15.3% | -12.5% | -41.7% | |
| Q4 2023 | +32.4% | +11.1% | -5.6% | |
| Q3 2023 | +0.0% | +0.0% | +21.4% | |
| Q2 2023 | -13.3% | -13.0% | -51.1% | |
| Q1 2023 | -9.5% | -4.8% | -61.9% | |
| Q4 2024 | +0.0% | -13.6% | -13.6% | |
| Q3 2022 | -19.2% | -4.1% | -34.2% | |
| Q4 2022 | -19.2% | -4.1% | -34.2% | |
| Q2 2022 | +8.4% | -28.3% | -63.2% | |
| Q1 2022 | -18.2% | -20.7% | -51.5% | |
| Q4 2021 | -17.4% | -26.5% | -44.3% | |
| Q3 2021 | -16.3% | -31.3% | -43.3% | |
| Q2 2021 | -10.0% | -20.6% | -2.7% | |
| Q1 2021 | +16.8% | +8.1% | -14.5% | |
| Q4 2020 | -36.7% | -36.9% | -43.9% | |
| Q3 2020 | -3.7% | -10.6% | -11.8% | |
| Q2 2020 | -5.0% | -8.4% | +11.9% | |
| Q1 2020 | -2.0% | -0.4% | -35.2% | |
| Q4 2019 | -19.8% | -21.3% | +1.0% | |
| Q3 2019 | +0.8% | +5.1% | +34.9% | |
| Q2 2019 | -10.7% | -6.8% | -1.3% | |
| Q1 2019 | +31.8% | +59.6% | +49.9% | |
| Q4 2018 | -20.7% | -21.4% | -15.7% | |
| Q3 2018 | -9.8% | -12.1% | -8.8% | |
| Q2 2018 | -5.1% | -7.8% | +87.1% | |
| Q1 2018 | -11.4% | -15.6% | -46.9% | |
| Q4 2017 | -3.5% | -3.0% | -5.3% | |
| Q3 2017 | -3.2% | +2.4% | +13.7% | |
| Q2 2017 | -17.4% | -23.0% | -27.2% | |
| Q1 2017 | +2.2% | +8.6% | -0.5% | |
| Q4 2016 | -2.1% | -2.1% | +31.5% | |
| Q3 2016 | +0.9% | +0.9% | -1.7% | |
| Q2 2016 | -11.9% | -11.8% | +8.9% | |
| Q1 2016 | -6.9% | — | — | |
| Q4 2015 | +4.8% | — | — | |
| Q3 2015 | -6.4% | — | — | |
| Q2 2015 | -0.9% | — | — | |
| Q1 2015 | -2.7% | — | — | |
| Q4 2014 | +6.5% | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro